Cocrystal Pharma Receives $5 Million Investment from OPKO Health

Cocrystal Pharma, a biotechnology firm, announced a $5 million private placement from existing investor OPKO Health. OPKO acquired over 5.4 million shares at $0.9134 each, increasing its stake. This funding supports Cocrystal's norovirus program, which is expected to release Phase 1b data later in 2026, potentially advancing its drug development.